论文部分内容阅读
目的探讨心力衰竭患者神经内分泌激素和细胞因子的变化及缬沙坦对其影响。方法检测 4 8例心力衰竭患者及 2 0例健康者血内皮素 (ET 1)、血管紧张素Ⅱ (AngⅡ )和肿瘤坏死因子 α(TNF α)浓度。将 4 8例心力衰竭患者随机分为两组 :常规治疗组 2 6例 ,给予常规抗心力衰竭治疗 ;缬沙坦治疗组 2 2例 ,在常规治疗基础上加缬沙坦 80mg ,每日1次 ,两组患者均治疗 1个月。并设健康对照组 2 0例。观察ET 1、AngⅡ和TNF α治疗前后的变化。结果①心力衰竭患者ET 1、AngⅡ和TNF α水平显著高于对照组 (P <0 .0 1)。②两组患者治疗后心力衰竭症状均有明显改善 ,但以缬沙坦治疗后ET 1和TNF α水平下降显著 (P <0 .0 1)。结论神经内分泌激素及细胞因子与心力衰竭的发生、发展有关 ,缬沙坦治疗在改善心功能的同时 ,可降低心力衰竭患者神经内分泌激素和细胞因子水平。
Objective To investigate the changes of neuroendocrine hormones and cytokines in patients with heart failure and the effects of valsartan on them. Methods The levels of endothelin (ET 1), angiotensin Ⅱ (Ang Ⅱ) and tumor necrosis factor α (TNF α) were detected in 48 patients with heart failure and 20 healthy subjects. Forty-eight patients with heart failure were randomly divided into two groups: conventional treatment group 26 cases, given conventional anti-heart failure treatment; valsartan treatment group 22 cases, on the basis of conventional treatment with valsartan 80mg daily 1 Times, two groups of patients were treated for 1 month. And set 20 cases of healthy control group. The changes of ET 1, Ang Ⅱ and TNF α before and after treatment were observed. Results ① The levels of ET 1, AngⅡ and TNFα in patients with heart failure were significantly higher than those in the control group (P <0.01). ② The symptoms of heart failure in both groups were significantly improved after treatment, but the levels of ET 1 and TNFα decreased significantly after valsartan treatment (P <0.01). Conclusions Neuroendocrine hormones and cytokines are related to the occurrence and development of heart failure. Valsartan can reduce the levels of neuroendocrine hormones and cytokines in heart failure patients while improving heart function.